immunogenicity
(2)
The Dose Was Hiding in the Dilution
Crystal Bio Solutions built its business around a stubborn truth of drug development: the clinical decision can be only as good as the assay beneath it. Its new bet is to keep the test, the model, and the regulatory argument in the same conversation.
Aizen Therapeutics
Aizen Therapeutics is a San Diego, AI-driven biotech spun out of Caltech that designs Mirror Peptides - synthetic drugs built entirely from D-amino acids, the mirror image of the L-amino acids that make up natural proteins. Its DaX platform pairs generative AI with structural biology to design these molecules from scratch, aiming for drugs with the potency of biologics but greater stability, lower immunogenicity, and the potential to be taken orally. The company emerged from stealth in November 2024 with a $13M seed round.